In this session, new and future diabetes medications are reviewed.
Continuing Education Instructions and Disclosure Information
Contact hours available until 3/29/21.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Conferences Committee Disclosures:
Michael Koronkowski discloses a role as a consultant for the following: OptumRx, Inc., P&T advisor; HRSA-GWEP, co-investigator; White Crane Wellness Center, Senior Programs.
There are no other disclosures to declare.
Speakers Conflict of Interest Disclosure:
There are no disclosures to declare.
Commercial Support and Sponsorship:
No commercial support or sponsorship declared.
Accreditation Statement:
This session is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Gerontological Advanced Practice Nurses Association (GAPNA).
Anthony J. Jannetti, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Anthony J. Jannetti, Inc. is a provider approved by the California Board of Registered Nursing, Provider Number CEP5387.
Learning Outcome:
After completing this learning activity, the participant will be able to identify newer diabetes medications and future trends in diabetes pharmacological management.
Romil Patel
10/17/19 11:47 am
FYI. The drugs listed as examples under Meglitinides were incorrect.